Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

$3.1 million and $1.2 million for the quarters ended September 30, 2013 and 2012, respectively.  The increase of $1.8 million was primarily due to increased costs related to patent prosecution, personnel-related expenses, stock-based compensation expense and consulting for market research, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $8.7 million and $2.0 million for the three months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

Year-To-Date Results
Revenues were $25.8 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $11.1 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma.  In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013. 

Research and development expenses were $20.2 million and $30.1 million for the nine months ended September 30, 2013 and 2012, respectively.  The decrease of $10.0 million was primarily due to lower quizartinib research and development expenses.  This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, for which enrollment of patients was completed in late 2011. 

General and administrative expenses were $7.0 million and $4.5 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $2.5 million was primarily due to increased costs related to patent prosecution, stock-based compensation expense, personnel-related expenses and consulting for market res
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Kamal Rashid , PhD, ... and Training Center (BETC) and research professor of biology ... 2014 , an international two-day event focused on biomanufacturing ... Global Summits, the event will bring together leaders of ... to develop and produce human therapeutics. “The growth curve ...
(Date:9/23/2014)... VA (PRWEB) September 23, 2014 ATCC, ... is pleased to announce two important appointments to the ... Executive Vice President of Strategy and Technology and Dr. ... for the Standards Resource Center. Both roles are new ... H. Cypess, President and CEO at ATCC described the ...
(Date:9/23/2014)... Sept. 23, 2014  Age Defying Dermatology ® , ... has become one of the first clinics in the ... aesthetic laser for tattoo removal. The treatment safely and ... "For years, tattoo removal has been a lengthy, painful, ... "This is an opportunity to erase tattoo pigment more ...
(Date:9/23/2014)... 23, 2014   GenoSpace , a precision medicine ... tools to enable the broad use of genomic data ... has been awarded Phase I of a Fast Track ... Institutes of Health (NIH) to enable enhanced data access ... http://photos.prnewswire.com/prnh/20140922/147649 During the past ...
Breaking Biology Technology:Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 2Worcester Polytechnic Institute's Biomanufacturing Expertise to be Featured in Berlin 3ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories 2
... BOCA RATON, Fla., Oct. 30 Nabi,Biopharmaceuticals (Nasdaq: ... Group (ISS) and Glass Lewis & Co., two ... that stockholders of the,Company vote "FOR" the Company,s ... certain Corporate Shared Services assets to Biotest,Pharmaceuticals Corporation, ...
... (OTC,Bulletin Board: NNLX) a nano-biotechnology company announces the date ... meeting will take place at 1 PM on 12/28/07 ... A call-in number will be provided for,questions to management. ... days prior to the meeting. Shareholders of record as ...
... 30 /PRNewswire-FirstCall/ - ICBS Limited,(PINKSHEETS: ICBM), today announced ... Bacteria Bank Ltd., is a Bio medical ... for use in medical research, located,in Montreal Canada. ... a world,renowned bacteriologist. Dr. Karl Weiss is ...
Cached Biology Technology:RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale 2RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals' Proposed Asset Sale 3NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update 2NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update 3ICBS acquires 30% interest in Bacteria Bank Ltd. 2
(Date:9/23/2014)... body forms new tissues during the healing process, ... other. For years, scientists believed this communication happened ... Mellon University and the University of Pittsburgh have ... is equally if not more crucial. The findings, ... Proceedings of the National Academy of Sciences , ...
(Date:9/23/2014)... Research by Rice University scientists who are fighting a ... be a clinician,s most powerful ally. , "Recent research ... cyberwarfare against the immune system, and we studied the ... how we might turn the tables on cancer," said ... this week in the Early Edition of the ...
(Date:9/23/2014)... identified a gene mutation that causes aplastic anemia, ... marrow fails to produce normal amounts of blood ... had blood disorders, the researchers discovered a defect ... with crucial roles in normal cell function. , ... molecular-based treatments that bypass the gene defect and ...
Breaking Biology News(10 mins):The mechanics of tissue growth 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3Gene mutation discovered in blood disorder 2
... Holy Grails of nanotechnology, but nature has been producing ... scientists has taken a unique look at how thousands ... clusters that direct cell movement to select chemicals in ... complex periodic patterns in biological systems can be generated ...
... Alexopoulos Prize will be given to Dr. Brian Shaw, Texas ... 29 in Snowbird, Utah. The honor based on ... known as the Outstanding Early-Career Mycologist Award of the Mycological ... and four review papers in 12 years. Both the National ...
... This release is available in Spanish . ... technique consisting of the induction of neuronal degeneration neuronal for ... helpful for the study of retinitis pigmentosa (RP), a group ... than one million persons a year all over the world. ...
Cached Biology News:Spontaneous assembly 2Spontaneous assembly 3Spontaneous assembly 4Work in mice will contribute to the study of hereditary diseases that lead to blindness 2
...
... Continuing a tradition of progressive centrifuge design ... series. The Centra-CL3 and Centra-CL3R (refrigerated) general ... laboratory., Quality Control Over Sample Preparation ... lock up to 99 protocols and has ...
PP2B-Abeta (C-20)...
... 8-iso PGE2 is one of several isoprostanes ... is a potent renal vasoconstrictor in the rat. ... with IC50 values of 0.5 and 5 µM, ... the rat at a concentration of 4 mg/kg/min, ...
Biology Products: